CN105208876A - 离子交换膜的从细胞结合剂细胞毒性剂缀合物中去除杂质的用途 - Google Patents

离子交换膜的从细胞结合剂细胞毒性剂缀合物中去除杂质的用途 Download PDF

Info

Publication number
CN105208876A
CN105208876A CN201380061514.1A CN201380061514A CN105208876A CN 105208876 A CN105208876 A CN 105208876A CN 201380061514 A CN201380061514 A CN 201380061514A CN 105208876 A CN105208876 A CN 105208876A
Authority
CN
China
Prior art keywords
cell
mixture
binding agent
cytotoxic agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380061514.1A
Other languages
English (en)
Chinese (zh)
Inventor
X·李
W·程
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunogen Inc
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of CN105208876A publication Critical patent/CN105208876A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
CN201380061514.1A 2012-10-04 2013-10-04 离子交换膜的从细胞结合剂细胞毒性剂缀合物中去除杂质的用途 Pending CN105208876A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709871P 2012-10-04 2012-10-04
US61/709,871 2012-10-04
PCT/US2013/063503 WO2014055893A1 (en) 2012-10-04 2013-10-04 Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates

Publications (1)

Publication Number Publication Date
CN105208876A true CN105208876A (zh) 2015-12-30

Family

ID=50435480

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380061514.1A Pending CN105208876A (zh) 2012-10-04 2013-10-04 离子交换膜的从细胞结合剂细胞毒性剂缀合物中去除杂质的用途

Country Status (13)

Country Link
US (1) US20150307596A1 (enExample)
EP (1) EP2903450A4 (enExample)
JP (1) JP2015535215A (enExample)
CN (1) CN105208876A (enExample)
AU (1) AU2013326897A1 (enExample)
CA (1) CA2886996A1 (enExample)
HK (1) HK1213148A1 (enExample)
IL (1) IL238111A0 (enExample)
IN (1) IN2015DN03203A (enExample)
MX (1) MX2015004258A (enExample)
RU (1) RU2015116883A (enExample)
SG (1) SG11201502430QA (enExample)
WO (1) WO2014055893A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108549763A (zh) * 2018-04-09 2018-09-18 电子科技大学 一种用于离子推进器数值模拟的电荷交换碰撞mcc方法
CN109789385A (zh) * 2016-10-03 2019-05-21 通用电气医疗集团生物工艺研发股份公司 新型色谱介质
CN118290514A (zh) * 2024-06-05 2024-07-05 东曜药业有限公司 基于阴离子膜的抗体偶联药物的纯化方法及抗体偶联药物
CN118290513A (zh) * 2024-06-05 2024-07-05 东曜药业有限公司 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
MX2011012794A (es) 2009-06-03 2012-05-08 Immunogen Inc Metodos de conjugacion.
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
WO2014055877A1 (en) * 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057163A2 (en) * 2002-01-03 2003-07-17 Smithkline Beecham Corporation Methods for preparing immunoconjugates
CN101267841A (zh) * 2005-08-24 2008-09-17 免疫原公司 制备美登木素生物碱抗体缀合物的方法
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
CN102448500A (zh) * 2009-06-03 2012-05-09 免疫基因公司 轭合方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
ES2503719T3 (es) * 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
ME03353B (me) * 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057163A2 (en) * 2002-01-03 2003-07-17 Smithkline Beecham Corporation Methods for preparing immunoconjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
CN101267841A (zh) * 2005-08-24 2008-09-17 免疫原公司 制备美登木素生物碱抗体缀合物的方法
CN102448500A (zh) * 2009-06-03 2012-05-09 免疫基因公司 轭合方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHARLOTTE F. MCDONAGH ET AL: "Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index", 《MOL CANCER THER》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789385A (zh) * 2016-10-03 2019-05-21 通用电气医疗集团生物工艺研发股份公司 新型色谱介质
CN108549763A (zh) * 2018-04-09 2018-09-18 电子科技大学 一种用于离子推进器数值模拟的电荷交换碰撞mcc方法
CN108549763B (zh) * 2018-04-09 2021-06-01 电子科技大学 一种用于离子推进器数值模拟的电荷交换碰撞mcc方法
CN118290514A (zh) * 2024-06-05 2024-07-05 东曜药业有限公司 基于阴离子膜的抗体偶联药物的纯化方法及抗体偶联药物
CN118290513A (zh) * 2024-06-05 2024-07-05 东曜药业有限公司 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物
CN118290513B (zh) * 2024-06-05 2025-03-14 东曜药业有限公司 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物
CN118290514B (zh) * 2024-06-05 2025-04-04 东曜药业有限公司 基于阴离子膜的抗体偶联药物的纯化方法及抗体偶联药物
WO2025251434A1 (zh) * 2024-06-05 2025-12-11 东曜药业有限公司 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物
WO2025251432A1 (zh) * 2024-06-05 2025-12-11 东曜药业有限公司 基于阴离子膜的抗体偶联药物的纯化方法及抗体偶联药物

Also Published As

Publication number Publication date
IL238111A0 (en) 2015-05-31
MX2015004258A (es) 2015-09-25
AU2013326897A1 (en) 2015-05-07
IN2015DN03203A (enExample) 2015-10-02
JP2015535215A (ja) 2015-12-10
RU2015116883A (ru) 2016-11-27
US20150307596A1 (en) 2015-10-29
CA2886996A1 (en) 2014-04-10
EP2903450A4 (en) 2016-05-11
EP2903450A1 (en) 2015-08-12
HK1213148A1 (zh) 2016-06-30
WO2014055893A1 (en) 2014-04-10
SG11201502430QA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
US11744900B2 (en) Preparation of maytansinoid antibody conjugates by a one-step process
US20120259100A1 (en) Process for manufacturing conjugates of improved homogeneity
RU2661083C2 (ru) Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
WO2012135517A2 (en) Preparation of maytansinoid antibody conjugates by a one-step process
CN105208876A (zh) 离子交换膜的从细胞结合剂细胞毒性剂缀合物中去除杂质的用途
JP2015504869A (ja) 複合体安定性を改善するためのｎ−ヒドロキシスクシンイミドの使用
NZ616509B2 (en) Preparation of maytansinoid antibody conjugates by a one-step process
NZ712414B2 (en) Preparation of antibody maytansinoid conjugates
NZ616516B2 (en) Process for manufacturing conjugates of improved homogeneity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151230